AVR · Anteris Technologies Global Corp.

Anteris Technologies Global Corp. disclosed its first quarter 2026 results under Item 2.02, furnishing Exhibits 99.1 and 99.2 with unaudited financial information and corporate updates filed with the ASX. The quarter reflected intense focus on the PARADIGM Trial, a pivotal randomized controlled study evaluating the DurAVR THV System against commercial TAVRs in approximately 1,000 patients. Net operating cash outflows reached $28.7 million, primarily attributable to clinical, regulatory, and manufacturing investments supporting trial execution. R&D expenses surged to $17.5 million, driven by manufacturing process design, validation, headcount growth, and clinical costs for patient enrollment and field team expansion, partially offset by lower DurAVR product research spending. These expenditures underscore the company's commitment to advancing toward global commercialization of its biomimetic DurAVR THV, designed with ADAPT tissue technology.

Operationally, the PARADIGM Trial saw continued European enrollment momentum post its Q4 2025 initiation, with U.S. sites activating after CMS coverage under TAVR NCD 20.32, enabling post-quarter patient enrollment. This reimbursement support is poised to accelerate site adoption and recruitment. Earlier in the quarter, Anteris secured $320 million in aggregate capital raises, bolstering its runway for trial completion and launch preparations. Clinical data presentations from the EMBARK Study and U.S. Early Feasibility Study at CRT 2026 and Sydney Valves 2026 enhanced scientific engagement. Related party payments of $2.3 million covered director fees and executive compensation, included in operating cash flows. CEO Wayne Paterson highlighted strong execution and U.S. momentum toward DurAVR commercialization. Investors should note the furnished nature of this disclosure, not deemed filed under the Exchange Act.